Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
RG

NASDAQ · RGC

Regencell Bioscience Holdings Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$6.15

Down-$0.40 (-6.43%)

Updated Nov 4, 2026, 6:36 PM

SID Score

3.8/10

Composite research score

Smart Money

56/100

Neutral

Market cap
8.33B
P/E ratio
-2,324.68
Dividend yield
0.00%
52-week range
$4.51 – $69.00
Volume
95.18K
Avg. volume
194.68K

Price performance · RGC

RGC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

RGC closed at $6.15 after 21 trading sessions, down 16.33% for the selected period.

Last close
$6.15
Period change
-16.33%
Period low
$6.15
Period high
$10.80
Daily close
View OHLC price history
RGC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$6.31$6.7685$6.1141$6.1595.18K
Nov 2, 2026$6.83$6.97$6.2101$6.2976.41K
Oct 30, 2026$6.89$7.0499$6.53$6.71148.17K
Oct 29, 2026$7.15$7.2499$6.72$6.86183.63K
Oct 28, 2026$7.61$7.8899$7.0601$7.27171.71K
Oct 27, 2026$6.70$7.4999$6.68$7.46255.96K
Oct 26, 2026$7.76$7.76$6.50$6.76450.56K
Oct 23, 2026$9.82$9.82$7.55$7.67476.53K
Oct 22, 2026$10.56$10.79$9.72$9.81275.44K
Oct 21, 2026$10.43$11.0196$10.42$10.80246.61K
Oct 20, 2026$9.94$10.95$9.20$10.45392.43K
Oct 19, 2026$9.32$11.305$9.06$10.05836.12K
Oct 16, 2026$10.305$10.33$8.83$9.59688.21K
Oct 15, 2026$7.98$11.1199$7.72$9.521.92M
Oct 14, 2026$8.20$9.47$7.82$8.11658K
Oct 13, 2026$7.16$8.6499$7.085$8.19577.36K
Oct 12, 2026$7.23$7.40$6.8176$7.13131.19K
Oct 9, 2026$7.73$7.75$7.28$7.35118.72K
Oct 8, 2026$7.06$7.9573$7.06$7.63228.5K
Oct 7, 2026$7.35$7.35$7.0127$7.11109.91K
Oct 6, 2026$7.22$7.9239$6.845$7.35301.27K

Latest RGC news

The latest Smart Investors Daily articles mentioning RGC.

Stock researchCompany · Overview

RGC research

Overview

Company profile and research snapshot.

Company profile

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Regencell (RGC) Stock Looks Rich As DOJ Probe Raises Questions

Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value can support. With the spotlight back on the stock after a series of setbacks and scrutiny, the key issue for you is how that market price stacks up against what the business has actually built up in net assets. Over the past 5 years the stock has delivered a very large gain of about 20 times,...

Yahoo · Oct 17, 2026

How Investors Are Reacting To Regencell Bioscience Holdings (RGC) Wider Full Year Loss

Regencell Bioscience Holdings reported full year results for the period ended June 30, 2026, with a net loss of US$11.7 million and basic loss per share from continuing operations of US$0.0237, compared with US$3.58 million and US$0.0072 a year earlier. The widening loss suggests heavier pressure from operating costs or investment spending, which puts more attention on how Regencell Bioscience Holdings manages cash use and execution risk over time. Now the focus shifts to what this larger...

Yahoo · Oct 8, 2026

Is Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?

Full Year Earnings Put Regencell Bioscience Holdings In Focus Regencell Bioscience Holdings (NasdaqCM:RGC) released full year results to June 30, 2026, reporting a net loss of US$11.7 million compared with US$3.58 million the prior year. Basic and diluted loss per share from continuing operations were both US$2.37, up from US$0.72 a year earlier. This shift is likely driving fresh questions about the stock’s risk profile. Regencell Bioscience Holdings has been volatile, with the share price...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By